ASX Security code and description of the class of +securities the subject of the buy-back
HLS : ORDINARY FULLY PAID
The type of buy-back is:
On market buy-back
Total number of +securities bought back before previous day
4,277,073
Total number of +securities bought back on previous day
827,064
Refer to next page for full details of the announcement
Notification of buy-back
1 / 6
Notification of buy-back
Part 1 - Entity and announcement details
For personal use only
1.1 Name of entity
HEALIUS LIMITED
We (the entity named above) provide the following information about our buy-back.
1.2
Registration number type
Registration number
ACN
064530516
1.3
ASX issuer code
HLS
1.4 The announcement is
Update/amendment to previous announcement
1.4a Type of update
Daily buy-back notification
1.4b Reason for update
Daily buy-back notification
1.4c Date of initial notification of buy-back
15/3/2022
1.4d Date of previous announcement to this update
2/6/2022
1.5 Date of this announcement
7/6/2022
1.6 ASX Security code and description of the class of +securities the subject of the buy-back
HLS : ORDINARY FULLY PAID
Notification of buy-back
2 / 6
Notification of buy-back
Part 2 - Type of buy-back
2.1 The type of buy-back is: On market buy-back
For personal use only
Notification of buy-back
3 / 6
Notification of buy-back
Part 3 - Buy-back details
only
Part 3A - Details of +securities, price and reason
3A.1 Total number of +securities on issue in the class of
+securities to be bought back
578,865,208
use
3A.4 Does the entity intend to buy back a minimum
number of +securities
No
3A.5 Does the entity intend to buy back a maximum
number of securities
No
personal
3A.6 Name of broker or brokers who will offer to buy back +securities on the entity's behalf
Broker name:
Bell Potter Securities Limited
3A.9 Are the +securities being bought back for a cash consideration?
Yes
3A.9a Is the price to be paid for +securities bought back known?
No
3A.9a.1 In what currency will the buy-back consideration
be paid?
AUD - Australian Dollar
For
Part 3B - Buy-back restrictions and conditions
3B.1 Does the buy-back require security holder approval?
No
Notification of buy-back
4 / 6
Notification of buy-back
Part 3C - Key dates
only
On-marketbuy-back
3C.2 Proposed buy-back start date
30/3/2022
3C.3 Proposed buy-back end date
use
14/3/2023
personalFor
P rt 3D - Other Information
3D.1 Any other information the entity wishes to notify to ASX about the buy-back
Healius Limited (ASX: HLS) intends to buy back up to $100 million worth of HLS ORD over the next 12 months. The
buy-back will be managed within the 10/12 limit permitted by the Corporations Act. Healius intends to conduct the
buy-back having regard to the prevailing share price, market conditions, any incremental capital requirements and
unforeseen circumstances.
Notification of buy-back
5 / 6
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Healius Limited published this content on 06 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 June 2022 23:11:08 UTC.
Healius Limited is an Australia-based healthcare company. The Company operates through two segments: Pathology and Imaging. The Pathology segment is a provider of pathology services, including specialty pathology and clinical trials. The Imaging segment is a provider of imaging and scanning services at standalone imaging sites, hospitals, and medical centers. The Company has a network of pathology laboratories, collection centers, and diagnostic imaging centers. It provides specialty diagnostic services to consumers and their referring practitioners. The Companyâs brands include Laverty Pathology, QML Pathology, Dorevitch Pathology, Western Diagnostic Pathology, Genomic Diagnostics, Abbott Pathology, IQ Pathology, Vetnostics, TML Vetnostics, Agilex Biolabs, Lumus Imaging, and others. The Company provides healthcare services that are accessible and efficient while supporting the coordination and continuity of quality patient care.
HEALIUS LIMITED 
